Genelux Corporation Proposes Public Offering of Stock and Warrants

On May 23, 2024, Genelux Corporation, a late-stage clinical immuno-oncology company, announced the initiation of a public offering of its common stock, along with accompanying warrants. This offering is part of the company’s strategy to advance their clinical development programs. All the shares and accompanying warrants will be issued by Genelux, with the company also planning to grant underwriters a 30-day option to purchase an additional 15% of the offered common stock.

Guggenheim Securities is positioned as the sole book-running manager for this offering, while Newbridge Securities Corporation will act as the co-manager. The offering is contingent upon market conditions and other standard closing conditions, with no guarantees on the completion, size, or terms of the offering.

The shares are being offered based on a previously filed effective shelf registration statement with the U.S. Securities and Exchange Commission (SEC). The offering is made pursuant to a written prospectus and prospectus supplement, which are part of the registration statement. A preliminary prospectus supplement detailing the offering's terms will be filed with the SEC and can be accessed freely through the SEC's website. Interested parties can also request a copy from Guggenheim Securities' Equity Syndicate Department.

This announcement does not constitute an offer to sell or a solicitation to buy these securities and cannot be used for such purposes in any jurisdiction where such an offer or sale would be unlawful before registration or qualification under the securities laws of the said jurisdiction.

About Genelux Corporation

Genelux Corporation is a biopharmaceutical company in the advanced stages of clinical development, focusing on creating next-generation oncolytic immunotherapies for patients with challenging and aggressive solid tumors. Their leading product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified strain of the vaccinia virus currently under investigation in a Phase 3 trial named OnPrime/GOG-3076. This trial evaluates the efficacy and safety of Olvi-Vec combined with platinum-doublet and bevacizumab against the standard chemotherapy and bevacizumab treatment in patients with platinum-resistant or refractory ovarian cancer.

Genelux's innovation is powered by its proprietary CHOICE™ platform, which has facilitated the development of an extensive library of engineered oncolytic vaccinia virus immunotherapeutic candidates, including Olvi-Vec.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!